Castle Biosciences, Inc. CSTL
$34.96
$1.524.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 103.55M | 83.68M | 87.01M | 83.04M | 86.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 103.55M | 83.68M | 87.01M | 83.04M | 86.19M |
| Cost of Revenue | 23.70M | 20.53M | 18.32M | 18.70M | 17.63M |
| Gross Profit | 79.85M | 63.15M | 68.70M | 64.34M | 68.56M |
| SG&A Expenses | 66.12M | 64.90M | 56.73M | 55.91M | 58.07M |
| Depreciation & Amortization | 2.25M | 2.23M | 2.28M | 2.28M | 1.96M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 106.62M | 102.09M | 90.84M | 89.85M | 90.44M |
| Operating Income | -3.07M | -18.41M | -3.83M | -6.80M | -4.25M |
| Income Before Tax | -1.69M | -14.41M | -2.71M | -386.00K | -143.00K |
| Income Tax Expenses | 370.00K | 109.00K | -382.00K | 115.00K | -4.67M |
| Earnings from Continuing Operations | -2.06M | -14.52M | -2.33M | -501.00K | 4.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.06M | -14.52M | -2.33M | -501.00K | 4.52M |
| EBIT | -3.07M | -18.41M | -3.83M | -6.80M | -4.25M |
| EBITDA | 1.00M | -14.48M | -50.00K | -1.17M | 19.26M |
| EPS Basic | -0.07 | -0.49 | -0.08 | -0.02 | 0.16 |
| Normalized Basic EPS | -0.02 | -0.34 | -0.02 | -0.08 | -0.03 |
| EPS Diluted | -0.07 | -0.49 | -0.08 | -0.02 | 0.15 |
| Normalized Diluted EPS | -0.02 | -0.34 | -0.02 | -0.08 | -0.03 |
| Average Basic Shares Outstanding | 30.40M | 29.89M | 29.33M | 29.07M | 28.91M |
| Average Diluted Shares Outstanding | 30.40M | 29.89M | 29.33M | 29.07M | 29.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |